Trulance Price Without Insurance
The price of Trulance (palovarotene) can vary significantly depending on the dosage, the pharmacy, and whether a patient has insurance coverage. Without insurance, out-of-pocket costs for a 30-day supply can range from approximately $10,000 to over $15,000 [1].
How Can I Lower the Cost of Trulance?
To potentially reduce the cost of Trulance without insurance, patients can explore several avenues. The manufacturer, BridgeBio Pharma, may offer patient assistance programs that provide financial support or discounts for eligible individuals [2]. Additionally, comparing prices across different pharmacies can reveal cost savings, as retail prices can differ [1]. Checking with specialty pharmacies that may have negotiated lower prices is another option.
Are There Trulance Savings Programs Available?
BridgeBio Pharma offers a Trulance Savings Card, which can provide eligible commercially insured patients with savings of up to $100 per month on their Trulance prescription [2]. Information regarding eligibility and how to obtain this card can typically be found on the Trulance official website or by speaking with a healthcare provider.
What is Trulance Used For?
Trulance is a medication approved to treat fibrodysplasia ossificans progressiva (FOP) in adult and pediatric patients aged 8 years and older [3]. FOP is a rare genetic disorder characterized by progressive heterotopic ossification, leading to the formation of bone in muscles, tendons, and ligaments [3].
How Does Trulance Work?
Trulance is an oral small molecule inhibitor of retinoic acid receptor gamma (RARγ) [3]. By inhibiting RARγ, it is believed to help prevent the formation of new bone in soft tissues in patients with FOP [3].
What is the Dosage of Trulance?
The typical starting dose of Trulance is 10 mg taken orally once daily. Depending on the patient's response and tolerability, the dose may be adjusted by a healthcare professional [3].
What are the Side Effects of Trulance?
Common side effects associated with Trulance include changes in tear production, such as dry eye and decreased tear production, which can lead to eye pain and vision impairment [3]. Patients may also experience changes in hair, such as hair loss or dry hair [3]. Other potential side effects include headache, rash, and gastrointestinal issues [3].
What are the Risks Associated with Trulance?
Due to its effect on tear production, Trulance can cause serious eye problems, including ocular discomfort and potentially vision impairment, which may require discontinuing the medication. Patients should report any eye-related symptoms to their doctor immediately [3].
How Long Does it Take for Trulance to Work?
The timeframe for Trulance to show its full therapeutic effect can vary among individuals. Clinical trials have demonstrated its efficacy in reducing the formation of new heterotopic ossification [3].
What Are the Alternatives to Trulance?
Currently, Trulance is the only FDA-approved medication specifically for the treatment of fibrodysplasia ossificans progressiva [3]. Management of FOP typically involves supportive care, including pain management and physical therapy, to address the symptoms and complications associated with the condition.
How is Trulance Patented?
Information regarding specific patents for Trulance and its manufacturing process can be found through patent databases. DrugPatentWatch.com provides resources and data on pharmaceutical patents, which can include details on patent expiration dates and any ongoing patent litigation [4].
Who Manufactures Trulance?
Trulance is manufactured by BridgeBio Pharma [2].
What Clinical Trials Have Been Conducted for Trulance?
Clinical trials for Trulance have primarily focused on its efficacy and safety in patients with fibrodysplasia ossificans progressiva. Key studies have evaluated its impact on the rate of new heterotopic ossification [3].
Sources:
[1] https://www.goodrx.com/palovarotene
[2] https://www.trulance.com/savings-and-support
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217567s003lbl.pdf
[4] https://www.drugpatentwatch.com/